Skip to main content
. Author manuscript; available in PMC: 2010 Mar 1.
Published in final edited form as: Int J Oncol. 2009 Mar;34(3):729–742. doi: 10.3892/ijo_00000199

Figure 3.

Figure 3

CRAd-S-RGD exhibits enhanced oncolytic potency. U87MG, U118MG, U373MG, A172 and No. 10 glioma cells were infected with CRAd-S-RGD, AdRGD, or AdWT at the indicated doses (MOI/cell). After 10 days, adherent cells were stained with crystal violet. Data are representative examples of two independent sets of experiments.